E8-2980. Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of Invention Described in U.S. Provisional Patent Application Concerning Treatment of Ischemia-Reperfusion Injury with Lipid, Annexin, and Lipid-Annexin Complexes

AGENCY:

Department of the Army, DoD.

ACTION:

Notice.

SUMMARY:

In accordance with 37 CFR 404.4, 404.6 and 404.7, announcement is made of the availability for licensing of the invention described in U.S. Provisional Patent Application No. 60/786,527 entitled “Treatment of Ischemia-Reperfusion Injury with Lipid, Annexin, and Lipid-Annexin Complexes,” filed March 27, 2006. Foreign rights are also available (PCT/US2007/065125). The United States Government, as represented by the Secretary of the Army, has rights in this invention.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, [phone]. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, [phone], both at telefax [phone].

SUPPLEMENTARY INFORMATION:

Disclosed are lipids, annexin, and lipid-annexin complexes for use in the prevention and/or treatment of ischemia-reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.

Brenda S. Bowen,

Army Federal Register Liaison Officer.